Radient Pharmaceuticals Corporation fka RXPC

[livinginsv]

notice the evolution: Onko-Sure, onkoResult, DR70

unipharma dropped the O-S, but kept the DR70 . . . hmmmm . . . it could be nothing, but it is suspicious . . . if they do bring back the O-S trademark in a PR, then i'd bet they are still paying the 100k per year license fee . . .

from 2/18/15 (still onko-sure)

The company has made at the end of 2014 Onko-Sure DR-70 tumor markers domestic production license, and earlier this year the domestic sales of the exhibition ? business plans within three years to complete major Asia-Pacific countries (Japan, Korea, Australia, New Zealand, ASEAN countries, China to Turkey and more than twenty countries) of the market, taken the domestic market into the regional market and even the size of the global market.
Arima drugs combined with a number of expert consultants and research units, using the latest technology to Onko-Sure DR-70 continuous improvement, expect the development of a second generation of rapid screening products or more precisely the Bead Assay products, but also about Arima binding Onko- the third generation of research reagents Sure combo with other tumor markers, the future will have an exclusive patent protection for these products are made and exclusive.

http://uni-pharma.com/news_detail-4.html

from 4/8/15 (oncoresult, see pics)

Turkey OnkoResult (Pharmaline subsidiary) in the past two to three years to implement DR-70 clinical trials, the results exceeded expectations, supported by many local doctors and teaching hospitals; April in particular to the company to visit, distributor negotiated issues, will actively Government budget execution for people tracking and screening program for colorectal cancer, and gradually applied to other cancers, and help the company to promote the DR-70 to neighboring countries.

http://uni-pharma.com/news_detail-2.html

from 4/15/15 (DR70,see pics)

Media press conference, deputy director of the Department of Surgery attached invitation Taipei Medical University Hospital - Weibo Li, MD, speaker, and the theories of male cancer cases, invite major TV, newspapers, the Internet, and other media plane, approximately 20 interviews with several media here. Press conference focused on the focus, tracking the flow of colorectal cancer patients after surgery, the researchers confirmed that DR-70 cancer patients can be detected up to 71.6% CEA normal values of relapse in patients with early detection of condition changes provide a new choice. Press conference after the interview, the physician and patient Wei own experiences, live shows DR-70 testing process, the media reaction warm, smooth and successful completion of press conference.

http://uni-pharma.com/news_detail-1.html